Most Recent
AstraZeneca has won an interlocutory injunction barring Pharmacor from making a generic version of its blockbuster diabetes drug Forxiga while a patent case over the drug proceeds.
German drug maker Merck KGaA is fighting US drug company Merck Sharp & Dohme over the alleged use of the ‘Merck’ mark in Australia, five years after their intellectual property spat was settled.
Biotech Regeneron and drug company Bayer have resolved their appeal of a ruling that allowed generic pharmaceutical manufacturer Sandoz to launch a version of top selling macular degeneration drug Eylea.
Suspecting infringement of patents for its Parkinson's drug, Xadago, biopharmaceutical company Newron has won preliminary discovery of documents from generic drug maker Arrotex Pharmaceuticals.
Abbey Animal Health has appealed its loss in a suit seeking to invalidate rival Virbac's patent for an antiparasitic drug.
Abbey Animal Health has managed only a “pyrrhic victory" in a patent case against rival Virbac over an antiparasitic drug, and must withdraw its Levamox Duo product from the market, a court has found.
Biotech Regeneron and drug company Bayer have wasted no time in challenging a decision that cleared the way for generic pharmaceutical manufacturer Sandoz to launch a version of top selling Eylea.
Regeneron and Bayer have lost their bid to block generic drug maker Sandoz from launching a biosimilar of their blockbuster eye drug Eylea.
A court has dismissed a lift supplier’s appeal of a decision rejecting its claim of breach of confidence against a rival, including an “entirely unwarranted” attack on solicitors at Allens over the use of documents obtained by “internet-savvy” search techniques.
Swiss aircraft manufacturer Pilatus has won discovery to pursue a possible copyright claim stemming from a Royal Australian Air Force flight simulator contract.